C1 Esterase Inhibitor Deficiency Research Articles

Analysis of the relationship between genetic mutation, clinical manifestations and prognosis in hereditary angioedema: scoping review protocol

Hereditary Angioedema (HAE) is a rare and severe genetic autosomal dominant disease of the immune system, caused by a deficiency of C1 esterase inhibitor (C1-INH). Classified into 3 subtypes: HAE with quantitative deficiency of the C1-INH inhibitor, C1-INH dysfunction, and normal C1-INH.The objective is to present a protocol examining the evidence on the relationship between mutations, clinical manifestations and prognosis in AEH. A systematic review will be conducted according to the steps: formulation of the clinical question (PICO), protocol with inclusion and exclusion criteria, conduction of a broad bibliographical search, extraction and summary of the included studies. This systematic review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Evidence will be obtained from the Pubmed, Embase, Web of Science and Scopus databases in the last 10 years. The selection of descriptors will be conducted using the Health Sciences Descriptors (DeCs), with the Boolean operators “AND and OR”, which will result in a search strategy for each proposed database. The selection will be conducted by two independent reviewers based on pre-determined criteria. In case of any discrepancy between the two reviewers, a third reviewer will mediate the conflict. Each study included will be assessed using the ROBINS-I, for the risk of bias, following the Oxford Evidence Base Center level of evidence and recommendation. Kappa Statistic will be used to assess inter-rater reliability. This systematic review will allow a greater understanding of HAE, and provide scientific evidence for healthcare professionals involved in the diagnosis and treatment of this disease.

Evolution of Guidelines for the Management of Hereditary Angioedema due to C1 Inhibitor Deficiency.

Hereditary angioedema (HAE) is a severe and disabling condition characterized by recurrent episodes of subcutaneous or mucosal swelling in the skin and respiratory and gastrointestinal tracts. HAE due to C1-esterase inhibitor deficiency (C1-INH-HAE) is the most prevalent subtype. The present Iberian study compared C1-INH-HAE treatment guidelines published between 2010 and 2022 to identify the main differences in therapeutic approaches for on-demand treatment and short- and long-term prophylaxis (LTP). HAE guidelines evolved with the availability of new treatments and with a change in the management paradigm towards an individualized, patient-centered approach, where quality of life (QOL) is central. A parallel trend was observed towards increasingly frequent home-based treatment, which potentially facilitates timely interventions, provides greater flexibility and convenience, and is associated with increased QOL, enabling patients to lead more normal lives. Most innovations over the years were made for LTP, together with the advent of new therapies and awareness of patients' needs. Several prophylactic therapies with a high level of evidence became available, although formal head-to-head comparisons are lacking. The treatment goals became more ambitious, ranging from a reduction in the frequency, severity, and duration of attacks to achieving total disease control and normalization of patients' lives. The document also addresses relevant items such as changes in terminology (eg, the introduction of designations as "first-line") and the introduction of patient-reported outcome measures to assess patients' perceptions of their self-experienced QOL and well-being. Unmet needs in the management of C1-INH-HAE are identified.

STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema.

Hereditary angioedema (HAE) is a rare autosomal dominant disorder caused by a deficiency in functional C1 esterase inhibitor (C1-INH), a serpin family protein that blocks the activity of plasma kallikrein. Insufficient inhibition of plasma kallikrein results in the overproduction of bradykinin, a vasoactive inflammatory mediator that produces both pain and unpredictable swelling during HAE attacks, with potentially life-threatening consequences. We describe the generation of STAR-0215, a humanized immunoglobulin G1 (IgG1) antibody with a long circulating half-life (t1/2) that potently inhibits plasma kallikrein activity, with a >1000-fold lower affinity for prekallikrein and no measurable inhibitory activity against other serine proteases. The high specificity and inhibitory effect of STAR-0215 is demonstrated through a unique allosteric mechanism involving N-terminal catalytic domain binding, destabilization of the activation domain, and reversion of the active site to the inactive zymogen state. The YTE (M252Y/S254T/T256E) modified fragment crystallizable (Fc) domain of STAR-0215 enhances pH-dependent neonatal Fc receptor (FcRn) binding, resulting in a prolonged t1/2 in vivo (⁓34 days in cynomolgus monkeys) compared to antibodies without this modification. A single subcutaneous dose of STAR-0215 ({greater than or equal to} 100 mg) was predicted to be active in patients for 3 months or longer, based on simulations using a minimal physiologically based pharmacokinetic (mPBPK) model. These data indicate that STAR-0215, a highly potent and specific antibody against plasma kallikrein with extended t1/2, is a potential agent for long-term preventative HAE therapy administered every 3 months or less frequently. Significance Statement STAR-0215 is a YTE-modified immunoglobulin G1 monoclonal antibody with a novel binding mechanism that specifically and potently inhibits the enzymatic activity of plasma kallikrein and prevents the generation of bradykinin. It has been designed to be a long-lasting prophylactic treatment to prevent attacks of HAE and to decrease the burden of disease and the burden of treatment for people with HAE.

A Comprehensive Management Approach in Pediatric and Adolescent Patients With Hereditary Angioedema.

Hereditary angioedema (HAE) is a rare autosomal-dominant disorder; most cases are characterized by low plasma levels of C1 esterase inhibitor (C1-INH). Clinical manifestations of HAE due to C1-INH deficiency include unpredictable, acute, recurrent episodes of nonpruritic swelling that can affect the face, trunk, limbs, and the respiratory, gastrointestinal, and genitourinary tracts. Attacks can be disfiguring, disabling, painful, and even life-threatening if laryngeal swelling occurs. Symptoms of HAE generally manifest in childhood. Effective medications are available and approved to treat HAE in children. However, evidence informing use of these medications in pediatric clinical practice is limited. Hereditary angioedema management plans are critical to optimize outcomes and should address on-demand treatment for acute attacks and plans to prevent potentially fatal laryngeal attacks. The plan should also comprise a holistic approach to address nonclinical aspects of HAE, including quality of life (QoL) and psychological issues. This article provides an overview of HAE management principles that health care providers can apply to treat pediatric patients to improve their QoL.

Burden of illness seen in hereditary angioedema in Japanese patients: Results from a patient reported outcome survey.

Hereditary angioedema (HAE) is a potentially life-threatening rare disease, which is mainly caused by the deficiency or dysfunction of C1-esterase inhibitor, and characterized by spontaneous, recurrent episodes of edema in various parts of the body including internal organs and the laryngeal area. Delayed diagnosis and treatment increase the burdens and risks of this condition. The current study aimed to understand the burden of illness for HAE patients in Japan before and after diagnosis through a patient reported outcome survey. A survey instrument was distributed to 121 adult patients with HAE by a patient organization via HAE treating physicians between July and November in 2016. Seventy patients (57.9%) returned the questionnaire. Patients reported high levels of medical resource utilization, including emergency procedures and services. Episodes of receiving laparotomy were somewhat less after diagnosis with HAE than before, but no apparent difference in episodes of tracheotomy between before and after the diagnosis. The economic burden, including direct and indirect medical costs, was highest before diagnosis, but still perceived as substantial after diagnosis. Patients reported disruption of work and school life, with 40% reporting that they miss 10 or more days from work or education per year. Sixty percent of patients reported that HAE affected their daily activities. We concluded that HAE is associated with considerable physical, social, economic and psycho-social burdens even after diagnosis, and that higher attack frequency is associated with a heavy disease burden for patients in Japan.

Analysis of the Association of Allergic Disease in Pediatric Patients with Hereditary Angioedema

Hereditary angioedema (HAE) is a rare autosomal dominant disease that is derived from the deficiency or dysfunction of C1 esterase inhibitor (C1-INH). In studies about the diseases that can accompany hereditary angioedema, allergic diseases occur more frequently compared to the healthy population but no studies on this issue have been carried out. This study was conducted in order to determine the frequency of the comorbidity of atopic sensitivity and allergic diseases in patients with hereditary angioedema. 32 patients who were diagnosed with hereditary angioedema in the Paediatric Allergy Polyclinic of Mersin City Hospital between 2019 and 2021 were included in the study. In these patients, the information about the existence of atopic diseases was obtained from their files and recorded. While asthma was observed in 6 (18.8%), allergic rhinitis in 18 (46.9%), and urticaria in 2 (6.2%) patients, dermatitis was not observed in any of the patients. While Fx5 test was positive in 5 (15.6%) patients, inhalant allergen mix sps IgE was positive in 7 (25.9%) patients. The IgE value was above 100 in 12 (52.2%) patients, and the eosinophil level was above 4% in 16 (50%) patients. In conclusion, we speculate in this study that the association of atopic disease and atopic sensitivity is observed more frequently in patients with angioedema than in the healthy population. However, a study with a larger sample is necessary to confirm this finding.

New medications to mitigate attacks of hereditary angioedema: does one size fit all?

Hereditary angioedema has received renewed attention in the past two decades, with the elucidation of the biochemical pathways resulting in bradykinin overproduction in patients with congenital C1esterase inhibitor (C1INH) deficiency, leading to recurrent attacks of tissue swelling due to uncontrolled vascular permeability. 1 Busse PJ Christiansen SC Hereditary angioedema. N Engl J Med. 2020; 382: 1136-1148 Crossref PubMed Scopus (132) Google Scholar Oedema attacks affecting the lingual or laryngeal area can become lethal as a result of asphyxiation. 2 Minafra FG Gonçalves TR Alves TM Pinto JA The mortality from hereditary angioedema worldwide: a review of the real-world data literature. Clin Rev Allergy Immunol. 2022; 62: 232-239 Crossref PubMed Scopus (4) Google Scholar Several new treatments have emerged, 143 years after Quincke's first description of hereditary angioedema and 15 years after the introduction of the first specific bradykinin B2 receptor inhibitor (icatibant). These drugs specifically target crucial steps in the kallikrein–kinin (contact) cascade downstream of bradykinin production. 3 Fijen LM Bork K Cohn DM Current and prospective targets of pharmacologic treatment of hereditary angioedema types 1 and 2. Clin Rev Allergy Immunol. 2021; 61: 66-76 Crossref PubMed Scopus (0) Google Scholar Many of these agents have shown their efficacy and safety in acute (on-demand) treatment and prophylaxis of hereditary angioedema attacks, saving lives and revolutionising patients’ quality of life. 4 Lumry WR Settipane RA Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020; 41: S08-S Crossref Google Scholar These modalities fit well into the modern paradigm in hereditary angioedema treatment, supporting patients’ autonomy, recommending self-administration, and reducing reliance on hospital emergency rooms, health-care providers, and medical points of care. 5 Maurer M Magerl M Betschel S et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. Allergy. 2022; 77: 1961-1990 Crossref PubMed Scopus (32) Google Scholar An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trialOral administration of sebetralstat was well tolerated and led to rapid suppression of plasma kallikrein activity, resulting in increased time to use of conventional attack treatment and faster symptom relief versus placebo. Based on these results, a phase 3 trial to evaluate the efficacy and safety of two dose levels of sebetralstat in adolescent and adult participants with hereditary angioedema has been initiated ( NCT05259917 ). Full-Text PDF

Diagnostic value of copy number identification of the SERPING1 gene in patients with different types of hereditary angioedema associated with C1-esterase inhibitor deficiency

Diagnostic value of copy number identification of the SERPING1 gene in patients with different types of hereditary angioedema associated with C1-esterase inhibitor deficiency

The validity and reliability of a Thai version of the Angioedema Control Test: Which recall period is preferable?

The Angioedema Control Test (AECT) is a questionnaire that monitors disease control in patients with angioedema, with a recall period of 4 weeks (AECT-4wk) or 3 months (AECT-3mo). This study investigated the psychometric properties of a Thai version of the AECT. Of 54 patients, 46, 5, 2, and 1 had recurrent angioedema with chronic spontaneous urticaria, hereditary angioedema, idiopathic histaminergic angioedema, and acquired angioedema due to C1 esterase inhibitor deficiency, respectively. The AECT, Angioedema Activity Score (AAS), Dermatology Life Quality Index (DLQI), Angioedema Quality of Life Questionnaire (AE-QoL), and anchors for disease control (numeric rating scale [NRS] and patient global assessment-Likert scale [PatGA-LS]) were used. The patients rated the efficacy of their treatment. Fifty-four and 47 patients completed the AECT-4wk and AECT-3mo, respectively. Both AECT versions showed significant correlations with disease activity (AAS, r = 0.6-0.8), disease control (NRS and PatGA-LS, r = 0.7-0.9), and quality of life impairment (DLQI and AE-QoL, r = 0.6-0.8). Higher correlations were found for the AECT-4wk than for the AECT-3mo. Excellent internal consistency (alpha = 0.98 and 0.97, respectively) and intraclass correlation (0.96 and 0.94, respectively) were found. A cutoff ≥ 10 was confirmed to identify patients with well-controlled disease for both AECT versions (AUCs = 0.89 and 0.97). The Thai version of the AECT is a valid and reliable tool for clinical practice. Due to the shorter recall period, the AECT-4wk may be more accurate than, and preferable to, the AECT-3mo. A cutoff ≥ 10 should be used to identify patients with well-controlled disease.

HPR131 Benefit Package of Universal Coverage Scheme for Hereditary Angioedema (HAE) Caused by C1 Esterase Inhibitor Deficiency (C1-INH)

HPR131 Benefit Package of Universal Coverage Scheme for Hereditary Angioedema (HAE) Caused by C1 Esterase Inhibitor Deficiency (C1-INH)

PD50 Value Of Healthcare Journey For Patients With Rare Diseases In The Brazilian Public Healthcare System: Methods And Preliminary Results

IntroductionImplementing value-based healthcare (VBHC) services requires the ability to assess and integrate evolution of patient-centered outcomes (PCO), clinical/epidemiological data and resource consumption. Aligned with Porter’s framework of value, the “Value of Healthcare Journey for Patients With Rare Diseases Project” (JAV-RARAS) was implemented to evaluate the value of the healthcare journey of patients with rare diseases (RD) in the Brazilian Public Healthcare System (SUS). The goal of this project is to identify the value (clinical outcomes and costs) associated with the management of RD in the SUS.MethodsPatients diagnosed with eight pre-defined RD under active clinical follow-up in SUS medical centers were invited. Retrospective data on diagnosis and assistance carried out after diagnosis were collected from medical records. Prospective follow-up of one year will be collected through validated clinical questionnaires on three visits, with an average interval of 6 months. Clinical outcomes include exams and disease-specific features, quality of life, productivity loss, treatment adherence and satisfaction. Total cost of patient’s journey in each medical center will be assessed through Time-Driven Activity-Based Costing method. All data collection is being carried out through the Think Patient Value (TPValue®), a computerized management support system, based on Porter’s paradigm of value.ResultsThirty-five medical centers currently assisting patients with RD were enrolled, representing all macro-regions in Brazil: Midwest (n=4), North (n=5), Northeast (n=10), South (n=5) and Southeast (n=11). Recruitment started in March, and until November 2021, 28 centers had reported retrospective data of at least one RD. So far, JAV-RARAS recruited patients with osteogenesis imperfecta (number of patients=106), phenylketonuria (n=52), familial amyloidotic polyneuropathy (n=32), classical homocystinuria (n=25), Prader–Willi syndrome (n=30), acromegaly (n=33), hereditary angioedema associated with C1 esterase-inhibitor deficiency (n=42) and mucopolysaccharidosis type-II (n=17).ConclusionsFuture results of JAV-Raras real-world evidence study will bring PCO and costs according to Porter’s Value, bringing insights for decision-makers in SUS. This study was funded by National Council for Scientific and Technological Development –CNPq and Ministry of Health of Brazil –MoH.

EE681 Costs of Treating Acute Hereditary Angioedema (HAE) Attacks With C1 Inhibitors in Five Central and Eastern European Countries

Hereditary angioedema (HAE) is a rare genetic disease caused by the deficiency or dysfunction of C1 esterase inhibitor (C1-INH), and characterized by recurring episodes of severe swelling, which can be life-threatening. Frequency and severity of attacks vary. Replacement C1-INH therapies provide effective relief; however, there is a lack of comparative data on economic outcomes in Central and Eastern European countries (CEE).

C1 Inhibitor Deficiency Results in Increased Activation of Coagulation and Enhanced Venous Thrombosis

Introduction: C1 esterase inhibitor (C1INH) is a broad acting serine protease inhibitor that functions as a major endogenous inhibitor of activated factor (F) XII, FXI and kallikrein of the contact system. Congenital deficiency for C1INH results in hereditary angioedema (HAE) that can cause potentially life-threatening episodes of bradykinin induced swelling. Patients with HAE have increased circulating markers of activation of coagulation, however, the effect of this procoagulant state on thrombosis remains unclear. Methods: Contact pathway triggered thrombin generation was assessed in citrated plasma from patients with HAE (n=19) or age and sex matched healthy controls (n=20) using calibrated automated thrombography. The association between HAE and risk of composite arterial thromboembolism (ATE) and composite venous thromboembolism (VTE) was analyzed in a registry-based study of HAE patients (n=239) and age and sex matched controls (n=2383) with data analyzed by conditional logistic regression. Markers of activation of coagulation were measured in the plasma of C1INH deficient mice or wildtype littermate controls. C1INH deficient mice or wildtype littermate controls were evaluated in the inferior vena cava stenosis model of venous thrombosis and the carotid artery ferric chloride model of arterial thrombosis. Hemostasis was assessed in C1INH deficient mice or wildtype littermate controls using a tail transection model. Results: Plasma from patients with HAE supported significantly increased intrinsic pathway-initiated thrombin generation compared to healthy controls reflected by significantly reduced lagtime and increased peak. Furthermore, the enhanced thrombin generation negatively correlated with residual plasma levels of C1INH activity. Given that enhanced plasma thrombin generation has been associated with an increased risk of VTE in the general population the association between HAE and VTE was further explored. HAE was found to be associated with a significantly increased risk of composite VTE (OR 3.57, 95% CI 2.16-5.81, P<0.0001) but not composite ATE (OR 1.20, 95% CI 0.81-2.09, P=0.278). Consistent with this finding the cumulative incidence of composite VTE, but not ATE, was significantly higher in patients with HAE compared to controls. C1INH deficient mice had significantly increased plasma levels of coagulation markers prothrombin fragment 1+2, thrombin-antithrombin complexes and D-dimer at baseline compared to wildtype littermate controls. In addition, C1INH deficient mice exhibited enhanced venous thrombus formation in the inferior vena cava stenosis model compared to wildtype littermate controls evidenced by increased thrombus weight. Interestingly, loss of C1INH had no effect on venous thrombus composition. Arterial thrombus formation in the carotid artery ferric chloride model was not significantly different between C1INH deficient mice and wildtype controls.Further, hemostasis, assessed using a tail transection model, did not differ significantly between C1INH deficient mice and wildtype littermate controls. Conclusions: Plasma from patients with HAE supported significantly increased contact pathway-initiated thrombin generation that was dependent on the degree of C1INH deficiency. HAE was found to be associated with a selective increase in the risk of composite VTE but not composite ATE. C1INH deficient mice had evidence of increased basal activation of coagulation consistent with impaired endogenous anticoagulant activity. Further, C1INH deficient mice exhibited increased venous thrombus formation but not arterial thrombus formation phenocopying findings in humans with HAE. This work strongly suggests that plasma C1INH is an important endogenous anticoagulant regulating basal activation of coagulation and providing selective protection against venous thrombus formation.

A CURIOUS CASE OF ACQUIRED ANGIOEDEMA: DIAGNOSIS AND MANAGEMENT OF C1-INH-AAE WITHOUT AN UNDERLYING CONDITION

<h3>Introduction</h3> Angioedema results from localized fluid extravasation into interstitial tissues mediated by mast cells, bradykinin, and other undescribed mechanisms. Recurrent bradykinin-mediated angioedema is most often hereditary, though can rarely be acquired due to autoantibody production. We present a case of acquired C1 esterase inhibitor deficiency (C1-INH-AAE) requiring tracheotomy, and review additional evaluation and maintenance therapy following diagnosis. <h3>Case Description</h3> An 80-year-old woman with multiple comorbidities was referred after two episodes of facial angioedema without clear triggers, including severe recurrence involving her oropharynx that required tracheotomy. Family history was negative, and both losartan and NSAIDs were previously discontinued. Initial evaluation following episode demonstrated indeterminate C1 inhibitor functional assay, low quantitative C1 inhibitor, and borderline C4 level; C1-INH-AAE was subsequently confirmed with C1 esterase autoantibody evaluation. She was prescribed icatibant rescue therapy and started on cetirizine and prednisone 5mg every other day without further recurrence of oropharyngeal symptoms. No evidence of underlying oncologic or rheumatologic process was found on extensive evaluation. During ongoing management over 5 years, tracheotomy was taken down, daily antihistamine was discontinued, and prednisone has been successfully titrated for symptoms associated with local tissue damage and iron deficiency anemia. <h3>Discussion</h3> C1-INH-AAE is a rare cause of recurrent angioedema which presents in older age and is often associated with underlying lymphoproliferative, malignant, or autoimmune disease. Our case reminds that acquired angioedema should be considered in older adults with negative family history, however had no evidence of commonly associated conditions on extensive evaluation. Her subsequent course also offers insight into management of triggers and maintenance therapy.

COMPLETE RESOLUTION OF ACQUIRED ANGIOEDEMA FROM SPLENIC MARGINAL ZONE LYMPHOMA AFTER TREATMENT WITH RITUXIMAB

<h3>Introduction</h3> Acquired angioedema (AAE) due to C1 esterase inhibitor (C1-INH) deficiency is clinically similar to hereditary angioedema (HAE), but typically develops in older patients. There is invariably an underlying disease such as a lymphoproliferative disorder, autoimmune condition, solid tumor, etc. that either drives autoantibody production against normal C1-INH and/or causes consumptive depletion of normally functioning C1-INH. <h3>Case Description</h3> A 68-year-old Caucasian male with past medical history of hypertension, presented 1 year previously with an episode of lip angioedema followed by recurrent episodes of abdominal pain lasting > 12 hours, associated early satiety, and gradual weight loss. He also developed peripheral neuropathy, splenomegaly of unclear etiology, and hypogammaglobulinemia. Workup of his angioedema led to the discovery of low C4 and C1-INH levels, and prophylactic treatment with Icatibant was initiated to treat further attacks. Given his age, splenomegaly, weight loss, and other clinically relevant information, he was evaluated for malignancy, especially lymphoproliferative disorders. He was subsequently diagnosed with Splenic Marginal Zone Lymphoma (SMZL), a clonal B cell neoplasia, and received one cycle of Rituximab with profound improvements of his angioedema-related symptoms, splenomegaly, and labs, including normalization of his quantitative C1-INH and C4 levels and hypogammaglobulinemia. <h3>Discussion</h3> Acquired angioedema in the form of C1-INH deficiency in older patients is often one of the initial manifestations of lymphoproliferative disorders and can present with prolonged episodes of abdominal pain. SMZL is highly associated with AAE, and prompt diagnosis and treatment of malignancy associated angioedema and other paraneoplastic manifestations can have a profound impact on clinical symptoms and quality of life.

Angioedema of Vermilion Border Lip: A Case Report

Angioedema is the diffuse edematous swelling of the soft tissues that most commonly involves the submucosal and subcutaneous connective tissues. It can also affect the connective tissues of the respiratory and gastrointestinal tract. The most common pathogenesis is the degranulation of mast cells, leading to histamine release and increased vascular permeability. The immunoglobulin E (IgE)-mediated hypersensitivity reactions are triggered by foods, preservatives such as sodium benzoate used in peanut butter, dust, drugs like angiotensin-converting enzyme inhibitors (ACE) like captopril, enalapril, lisinopril and pollens, and contact allergies started by prolonged contact with dental rubber dams and cosmetics. Hereditary factorssuch as quantitative reduction of C1 esterase inhibitor (C1-INH) deficiency and dysfunctional C1 esterase inhibitor (C1-INH)are also postulated in its etiopathogenesis. In addition, lymphoproliferative disorders, bacterial or viral infections, lupus erythematosus, and minor trauma from dental procedures may precipitate an angioedema attack.

Systemic lupus erythematosus with various clinical manifestations in a patient with hereditary angioedema: a case report

BackgroundHereditary angioedema (HAE) is an inherited disease characterized by recurrent angioedema without urticaria or pruritus. The most common types of HAE are caused by deficiency or dysfunction in C1 esterase inhibitor (C1-INH-HAE). The association between C1-INH-HAE and systemic lupus erythematosus (SLE) is known; however, variations in the underlying pathophysiology, disease course, and treatment in this population remain incompletely understood.Case presentationA 31-year-old Japanese woman with a prior diagnosis of HAE type 1 based on the episodes of recurrent angioedema, low C1 inhibitor antigen levels and function, and family history presented with new complaints of malar rash, alopecia, and arthralgias in her hands and elbows. She later developed fever, oral ulcers, lupus retinopathy, a discoid rash localized to her chest, and malar rash. Investigations revealed positive antinuclear antibody, leukopenia, thrombocytopenia, hypocomplementemia, and nephritis. Based on these findings, she was diagnosed with SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria. There did not appear to be a correlation between HAE disease activity and the timing of presentation with SLE, because HAE disease activity had been stable. The patient was able to achieve and maintain remission with immunosuppressive therapy including prednisolone, hydroxychloroquine, and tacrolimus.ConclusionsOur patient presented with a variety of symptoms, including fever and cytopenia in addition to mucocutaneous, joint, ocular, and renal lesions. It is important to better characterize the clinical characteristics of SLE in patients with C1-INH-HAE, and to clarify the mechanisms of SLE in this population.

Immunogenicity and Safety of mRNA Anti-SARS-CoV-2 Vaccines in Patients with Systemic Lupus Erythematosus.

Vaccination is the most effective preventive measure to control the spread of COVID-19 and reduce associated complications. This study aims to evaluate the efficacy and safety of mRNA COVID-19 vaccines in patients with systemic lupus erythematosus (SLE). A total of 41 adult SLE patients receiving two doses of the SARS-CoV-2 mRNA Comirnaty-BioNTech/Pfizer vaccine were enrolled. The quantitative determination of anti-trimeric spike protein-specific IgG antibodies to SARS-CoV-2 was assessed before (T0), 21 days after the administration of the first dose of the vaccine (T1), and between 21 and 28 days after the second dose (T2). They were compared with the same determinations from a cohort of 29 patients with C1-esterase inhibitor deficiency hereditary angioedema (C1-INH-HAE) as controls. All the SLE patients and controls demonstrated a positive serological response after a single dose of the vaccine (T1), which significantly increased after the second dose (T2). No significant difference was found between SLE patients and controls at T1 [t(52.81) = −0.68; p = 0.49] and at T2 [t(67.74) = −0.22; p = 0.825]. Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) analysis showed that the vaccine did not influence SLE activity or caused disease flare in our cohort. In conclusion, COVID-19 vaccines produced a satisfactory response in SLE patients without variation in the disease activity.

EE39 Costs of Treating Hereditary Angioedema (HAE) Attacks with C1 Inhibitors in Four European Countries

Hereditary angioedema (HAE) is a rare genetic disease caused by the deficiency or dysfunction of C1 esterase inhibitor (C1-INH), and characterized by recurring episodes of severe swelling, commonly affecting the skin, gastrointestinal tract, or upper airway (which can be life-threatening). Frequency and severity of attacks vary. Replacement C1-INH therapies provide effective relief; however, there is a lack of comparative data on economic outcomes.

Angioedema and anaphylaxis, a family story

Non-allergic angioedema has a worrying morbidity. Clinical examination is central, as C1-esterase inhibitor deficiency will not be documented in the acute phase. In the case of anaphylaxis that does not respond toadrenaline, an early diagnosis can optimise referral of the patient to a reference healthcare establishment for a specific therapeutic protocol (icatibant, C1 inhibitor) recently updated by recommendations.